CY1124949T1 - Αντισωμα - Google Patents

Αντισωμα

Info

Publication number
CY1124949T1
CY1124949T1 CY20221100090T CY221100090T CY1124949T1 CY 1124949 T1 CY1124949 T1 CY 1124949T1 CY 20221100090 T CY20221100090 T CY 20221100090T CY 221100090 T CY221100090 T CY 221100090T CY 1124949 T1 CY1124949 T1 CY 1124949T1
Authority
CY
Cyprus
Prior art keywords
antibody
inhibition
exposed
effective against
glycosylation
Prior art date
Application number
CY20221100090T
Other languages
English (en)
Inventor
Naoki Hosen
Haruo Sugiyama
Atsushi Kumanogoh
Original Assignee
Osaka University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University filed Critical Osaka University
Publication of CY1124949T1 publication Critical patent/CY1124949T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Παρέχεται ένα αντίσωμα αποτελεσματικό σε αντιμετώπιση όγκων και των παρόμοιων. Το αντίσωμα αναγνωρίζει έναν επίτοπο ο οποίος περιέχει μια θέση Ν-γλυκοζυλίωσης ανθρώπινου CD98hc και ο οποίος εκτίθεται με αναστολή Ν-συνδεδεμένης γλυκοζυλίωσης.
CY20221100090T 2015-08-10 2022-02-02 Αντισωμα CY1124949T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015158414 2015-08-10
PCT/JP2016/073503 WO2017026497A1 (ja) 2015-08-10 2016-08-09 抗体

Publications (1)

Publication Number Publication Date
CY1124949T1 true CY1124949T1 (el) 2023-01-05

Family

ID=57984391

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100090T CY1124949T1 (el) 2015-08-10 2022-02-02 Αντισωμα

Country Status (15)

Country Link
US (3) US20180230212A1 (el)
EP (2) EP3336185B1 (el)
JP (1) JP6534074B2 (el)
CN (2) CN108138172B (el)
CA (1) CA2995166C (el)
CY (1) CY1124949T1 (el)
DK (1) DK3336185T3 (el)
ES (1) ES2905534T3 (el)
HR (1) HRP20220069T1 (el)
HU (1) HUE057499T2 (el)
LT (1) LT3336185T (el)
PL (1) PL3336185T3 (el)
PT (1) PT3336185T (el)
SI (1) SI3336185T1 (el)
WO (1) WO2017026497A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2905534T3 (es) * 2015-08-10 2022-04-11 Univ Osaka Anticuerpo
JP2020511498A (ja) * 2017-03-20 2020-04-16 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ａｌアミロイドーシスの治療のためのｃｓ１標的化キメラ抗原レセプター改変ｔ細胞
CA3090519A1 (en) 2018-02-07 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
MX2021004779A (es) * 2018-10-31 2021-06-08 I Mab Biopharma Us Ltd Anticuerpos cd47 novedosos y metodos para usarlos.
CN112194722A (zh) * 2020-09-10 2021-01-08 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 抗h5亚型禽流感病毒的重组抗体及其制备方法和应用
TW202322822A (zh) 2021-08-20 2023-06-16 日商大塚製藥股份有限公司 組合醫藥

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003001884A2 (en) * 2001-06-26 2003-01-09 Trustees Of Tufts College Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer
TWI390034B (zh) * 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
WO2007142309A1 (ja) * 2006-06-09 2007-12-13 Michio Ishibashi 腎糸球体治療剤のスクリーニング方法
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
JPWO2011118804A1 (ja) * 2010-03-26 2013-07-04 国立大学法人徳島大学 新規抗ｃｄ９８抗体とその用途
JP5906447B2 (ja) * 2011-01-13 2016-04-20 国立研究開発法人産業技術総合研究所 上皮性卵巣癌鑑別マーカー
MX2014006272A (es) * 2011-11-23 2014-10-24 Igenica Biotherapeutics Inc Anticuerpos anti-cd98 y metodos de uso de los mismos.
ES2905534T3 (es) * 2015-08-10 2022-04-11 Univ Osaka Anticuerpo

Also Published As

Publication number Publication date
EP3336185A1 (en) 2018-06-20
CA2995166C (en) 2023-10-31
JPWO2017026497A1 (ja) 2018-06-21
CN108138172A (zh) 2018-06-08
EP4005594A1 (en) 2022-06-01
PL3336185T3 (pl) 2022-02-28
DK3336185T3 (en) 2022-01-24
EP3336185A4 (en) 2019-01-16
HUE057499T2 (hu) 2022-06-28
PT3336185T (pt) 2022-01-27
ES2905534T3 (es) 2022-04-11
CN113683696A (zh) 2021-11-23
US20230357390A1 (en) 2023-11-09
US20220064287A1 (en) 2022-03-03
SI3336185T1 (sl) 2022-04-29
WO2017026497A1 (ja) 2017-02-16
CA2995166A1 (en) 2017-02-16
US20180230212A1 (en) 2018-08-16
HRP20220069T1 (hr) 2022-04-15
LT3336185T (lt) 2022-02-10
CN108138172B (zh) 2021-07-27
EP3336185B1 (en) 2021-12-22
JP6534074B2 (ja) 2019-06-26

Similar Documents

Publication Publication Date Title
CY1124949T1 (el) Αντισωμα
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
CY1123259T1 (el) Αντισωματα anti-pvrig και μεθοδοι χρησης
CY1124619T1 (el) Αντισωματα αντι-προ/λανθανουσας μυοστατινης και χρησεις αυτων
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
SV2018005659A (es) Anticuerpos agonistas que se unen especificamente a cd40 humanos y metodos de uso
CL2016001871A1 (es) Anticuerpos humanos para pd-1
EA201990615A1 (ru) Пирролобензодиазепиновые конъюгаты
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
BR112015032224A2 (pt) anticorpos anti-fcrh5
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CY1123019T1 (el) Σπειροκυκλικες ενωσεις
BR112017015880A2 (pt) anticorpos, usos e métodos
CL2017003295A1 (es) Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias
SV2016005352A (es) Anticuerpos antagonistas del interferon alfa y omega
BR112018002382A8 (pt) Novos anticorpos anti-gvpi humano e usos dos mesmos
CL2018000298A1 (es) Anticuerpos anti-cd154 y métodos de uso de estos.
DK3891642T3 (da) Fremgangsmåde til sikring af pålideligheden af kildekoder
DK3688530T3 (da) Strålingskilde